NO20014662L - Fremgangsmåter og preparater for behandling av faste tumorer - Google Patents

Fremgangsmåter og preparater for behandling av faste tumorer

Info

Publication number
NO20014662L
NO20014662L NO20014662A NO20014662A NO20014662L NO 20014662 L NO20014662 L NO 20014662L NO 20014662 A NO20014662 A NO 20014662A NO 20014662 A NO20014662 A NO 20014662A NO 20014662 L NO20014662 L NO 20014662L
Authority
NO
Norway
Prior art keywords
preparations
methods
solid tumors
treating solid
solid tumor
Prior art date
Application number
NO20014662A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014662D0 (no
Inventor
Wenbin Dang
Jr Robert I Garver
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of NO20014662D0 publication Critical patent/NO20014662D0/no
Publication of NO20014662L publication Critical patent/NO20014662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO20014662A 1999-03-26 2001-09-25 Fremgangsmåter og preparater for behandling av faste tumorer NO20014662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/276,866 US6537585B1 (en) 1999-03-26 1999-03-26 Methods and compositions for treating solid tumors
PCT/US2000/007304 WO2000057852A2 (en) 1999-03-26 2000-03-20 Methods and compositions for treating solid tumors

Publications (2)

Publication Number Publication Date
NO20014662D0 NO20014662D0 (no) 2001-09-25
NO20014662L true NO20014662L (no) 2001-11-20

Family

ID=23058398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014662A NO20014662L (no) 1999-03-26 2001-09-25 Fremgangsmåter og preparater for behandling av faste tumorer

Country Status (17)

Country Link
US (2) US6537585B1 (de)
EP (1) EP1185249B1 (de)
JP (2) JP2002540137A (de)
KR (1) KR20010111578A (de)
CN (1) CN1367684A (de)
AT (1) ATE306251T1 (de)
AU (1) AU778279B2 (de)
BR (1) BR0009213A (de)
CA (1) CA2368621C (de)
CZ (1) CZ20013260A3 (de)
DE (1) DE60023138T2 (de)
HU (1) HUP0201436A3 (de)
IL (1) IL145492A0 (de)
NO (1) NO20014662L (de)
PL (1) PL351280A1 (de)
TR (1) TR200102801T2 (de)
WO (1) WO2000057852A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US20020041897A1 (en) * 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002005800A2 (en) * 2000-07-17 2002-01-24 Guilford Pharmaceuticals, Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US7345138B2 (en) * 2001-05-14 2008-03-18 Johns Hopkins Singapore Pte Ltd. Biodegradable polyphosphates for controlled release of bioactive substances
US7417110B2 (en) * 2001-05-14 2008-08-26 Jun Wang Biodegradable polyphosphoramidates for controlled release of bioactive substances
AU2002354957A1 (en) * 2001-07-19 2003-03-03 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
WO2003060799A2 (en) * 2002-01-09 2003-07-24 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
WO2003080629A2 (en) 2002-02-25 2003-10-02 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
WO2005041936A2 (en) * 2003-10-21 2005-05-12 Psimedica Limited Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
NZ555571A (en) * 2004-12-06 2009-02-28 Sciclone Pharmaceuticals Inc Alpha thymosin peptides as cancer vaccine adjuvants
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN101287507B (zh) * 2005-08-12 2012-12-05 刘江 用于淋巴靶向的方法和装置
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
EP3009477B1 (de) 2006-07-20 2024-01-24 Orbusneich Medical Pte. Ltd Bioresorbierbare polymerzusammensetzung für eine medizinische vorrichtung
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
CN101390828B (zh) * 2007-02-12 2010-06-09 济南康泉医药科技有限公司 同载抗代谢类药物和增效剂的抗癌组合物
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
ES2362525B8 (es) * 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
EP2552415B1 (de) 2010-03-29 2016-09-07 Abraxis BioScience, LLC Verfahren zur behandlung von karzinomen
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP2566474B1 (de) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Nichtwässrige taxan-pro-emulsionsformulierungen sowie verfahren zu ihrer herstellung und verwendung
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
SG11201501850VA (en) * 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9545447B2 (en) 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
AU2016270559B2 (en) 2015-06-04 2020-12-10 Crititech, Inc. Collection device and methods for use
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
SG11202100854TA (en) 2018-10-16 2021-05-28 US Nano Food & Drug INC Intratumor injection formulation
WO2021211294A1 (en) 2020-04-13 2021-10-21 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation
GB2623319A (en) 2022-10-11 2024-04-17 Af Chempharm Ltd Method of synthesis of chloro-oxo-dioxaphospholane oxides and derivates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (de) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
NZ265555A (en) 1993-04-19 1997-09-22 Medisorb Technologies Internat Biodegradable microparticle compositions of antisense oligodeoxyribonucleotides
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
JPH09507233A (ja) 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
DE69731623D1 (de) 1996-04-23 2004-12-23 Ipsen Mfg Ireland Ltd Saure Polymilchsäure Polymere
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
IL132094A0 (en) 1997-03-27 2001-03-19 Baker Norton Pharma Methods and compositions for treatment of ovarian cancer
AU741145B2 (en) 1997-04-03 2001-11-22 Eisai Inc. Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
HUP0001299A3 (en) 1997-04-30 2001-09-28 Univ Johns Hopkins Med Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds and articles
WO1998058012A1 (en) 1997-06-18 1998-12-23 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
EP1117441A2 (de) 1998-10-02 2001-07-25 Guilford Pharmaceuticals Inc. Bioabbaubare terephthalat polyester-polyphosphonat und polyester-polyphosphit polymere,zusammensetzungen,gegenstände und verfahren für ihre verwendung
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
WO2000064437A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
US20020041897A1 (en) 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002005800A2 (en) 2000-07-17 2002-01-24 Guilford Pharmaceuticals, Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
AU2002354957A1 (en) 2001-07-19 2003-03-03 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
WO2003007915A2 (en) 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same

Also Published As

Publication number Publication date
DE60023138D1 (de) 2006-02-23
US7101568B2 (en) 2006-09-05
TR200102801T2 (tr) 2002-04-22
CZ20013260A3 (cs) 2002-01-16
HUP0201436A3 (en) 2003-04-28
US20030203033A1 (en) 2003-10-30
JP2002540137A (ja) 2002-11-26
BR0009213A (pt) 2002-04-16
ATE306251T1 (de) 2005-10-15
NO20014662D0 (no) 2001-09-25
KR20010111578A (ko) 2001-12-19
WO2000057852A3 (en) 2001-02-15
CA2368621C (en) 2010-05-25
JP2011219483A (ja) 2011-11-04
AU778279B2 (en) 2004-11-25
DE60023138T2 (de) 2006-08-17
CN1367684A (zh) 2002-09-04
WO2000057852A2 (en) 2000-10-05
EP1185249B1 (de) 2005-10-12
EP1185249A2 (de) 2002-03-13
IL145492A0 (en) 2002-06-30
PL351280A1 (en) 2003-04-07
HUP0201436A2 (en) 2002-09-28
CA2368621A1 (en) 2000-10-05
US6537585B1 (en) 2003-03-25
AU3762500A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
NO20014662L (no) Fremgangsmåter og preparater for behandling av faste tumorer
NO20013402D0 (no) Fremgangsmåter for behandling av ovarialcancer, poly(fosfoester)preparater, og bionedbrytbare gjenstander for detsamme
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
BG105108A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
WO2001082961A3 (en) Methods for treating bone tumors
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
BRPI0516265A (pt) composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
GR3035593T3 (en) Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
ATE232390T1 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
SE8403912D0 (sv) Lekemedelssats eller -komposition
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
ATE383863T1 (de) Kombinationschemotherapie
EP1208840A3 (de) Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
YU37402A (sh) Vakcina za lečenje upale prostate i benigne prostatne hiperplazije, koja obuhvata sojeve lactobacillus
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
CY1107256T1 (el) Χημειοθεραπεια συνδυασμου
WO2001042794A3 (en) Method for identifying inhibitors of cytokinesis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application